Dacomitinib is an EGFR inhibitor. It’s used to treat non-small cell lung cancer. It goes after certain mutations, like the EGFR exon 19 deletion or the L858R mutation in exon 21.
It works by stopping EGFR signals, which helps keep cancer cells from spreading and growing. Dacomitinib comes in tablet form and is available in 15, 30, and 45 mg doses. For people with EGFR mutation-positive NSCLC, the usual dose is 45 mg, taken every day.
You’ll find it in a bottle with 30 tablets inside.
